Insights

Aus BioTech Insights from Life Sciences Talent Specialist Sandra Kerr

Date Posted:1 November 2024
Author:Sandra Kerr

The annual AusBiotech conference stands out as a pivotal event in the life sciences sector, uniting our vibrant biotech community to engage in discussions about current topics and emerging trends. Industry leaders generously shared their experiences and insights, covering a wide range of subjects from early-stage innovation to Australia’s health security. This year’s event attracted record numbers of attendees from across Australia and around the globe.

CEO Rebekah Cassidy highlighted the presence of over 2,900 organisations, including nearly 1,600 biotech and medtech companies. The Hon. Minister Mark Butler stated that it is evident that Australia’s biotech sector possesses transformative potential for health, economic growth, and research leadership. The Minister highlighted Australia’s impressive global ranking—7th in health and medical research. However, the sector’s modest 0.3% contribution to GDP underscores an urgent need to leverage our research strengths to drive economic growth, secure jobs, and bolster Australia’s role in medical discovery.

The conference more broadly addressed critical policy issues affecting the sector, including national health security, supply chain resilience, and workforce capabilities. Australia is a prime location for life science companies due to its robust clinical trials capabilities. Around 1,000 new trials commence yearly, supported by world-class medical research infrastructure and efficient regulatory pathways. Moreover, the government offers incentives like the R&D Tax Incentive, fostering both local and international investments. With strong intellectual property protection and proximity to Asia, Australia remains an attractive global trade partner. The critical piece of the biotech puzzle is in fact a human piece; how might we attract and retain our world-class talent by focusing on the pipeline of innovation to commercialisation?

As we close 2024, it is imperative to address the lack of female leadership in Australian biotech and to explore how we can effect meaningful change.

One of the most impactful panels I attended posed a critical question: why does the underrepresentation of women in biotech leadership persist in 2024? The panelists passionately argued that with only 11% of biotech CEOs being female, we are missing out on the unique advantages that diversity offers, particularly in innovation-driven fields like ours. The conference resonated with the strong sentiment that gender diversity should no longer be up for discussion; it must become a reality. Research consistently shows that diverse boards and leadership teams outperform their peers; a 2022 study revealed that Australian companies with gender-diverse leadership report higher profit margins.

To truly shift the paradigm, our industry must commit to establishing structured support networks, dedicated programs for women entrepreneurs, and visible role models. Policies that promote flexible work arrangements, equal pay, and clear pathways for advancement are essential for fostering an inclusive culture that enhances employee satisfaction and reduces turnover. As industry leaders, how can we actively “send the ladder down” and cultivate a robust pipeline of future female leaders?

The discussions at AusBiotech reinforced the notion that closing this gender gap is not only a moral imperative but also a strategic advantage for the future of our sector.


Australian-Aboriginal-Flag Torres_Strait_Islanders_Flag Tino-Rangatiratanga-Maori-sovereignty-movement-flag

We acknowledge the first and continuing custodians of the countries and the grounds upon which we live, lead, and learn. We recognise the unique and enduring relationship that exists between Indigenous Peoples and the land the world over. We welcome their deep knowledge and lessons in stewardship.